Interpace Biosciences, Inc 8-K, filed Oct 15, 2026
Interpace Biosciences, Inc. (IDXG)
About this 8-K
Interpace Biosciences, Inc filed this 8-K on October 15, 2026, reporting on events of October 14, 2026.
Interpace Biosciences expects preliminary, unaudited Q3 2026 revenue of $10.1 million to $10.4 million, up approximately 11% to 14% from Q2 2026 and 15% to 18% from Q3 2025. AI summary
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address, including zip code, of principal executive offices)
Registrant’s telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| None | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On October 14, 2026, Interpace Biosciences, Inc. (the “Company”) issued a press release announcing preliminary results for the third quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number | Description | |
| 99.1 | Press Release dated October 14, 2026 | |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) |
Forward-Looking Statements
This report contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this report that are not historical facts may be considered “forward-looking statements,” including, but not limited to, statements regarding the Company’s preliminary results for the quarter ended September 30, 2026. These statements are based on management’s current expectations and information available as of the date of this report and are subject to risks, uncertainties, closing adjustments and other factors that could cause actual results to differ materially. Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology. Forward-looking statements are based on current expectations of management and upon what management believes to be reasonable assumptions based on information currently available to it, and are subject to risks and uncertainties. Such risks and uncertainties may cause actual results to differ materially from the expectations set forth in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks related to preliminary financial results, including the risks that the preliminary financial results reported in Exhibit 99.1 reflect information available to the Company only at this time and may differ from actual results, including in connection with the Company’s completion of financial closing procedures, risks and uncertainties associated with the Company’s business and finances in general, as well as other risks detailed in the Company’s recent filings on Forms 10-K and 10-Q with the SEC. The Company undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: October 15, 2026 | INTERPACE BIOSCIENCES, INC. | |
| By: | /s/ Thomas W. Burnell | |
| Name: | Thomas W. Burnell | |
| Title: | President and Chief Executive Officer | |
Exhibit 99.1
Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue
| ● | Preliminary Q3 2026 revenue expected to range from $10.1 million to $10.4 million | |
| ● | Expected quarter-over-quarter growth of approximately 11% to 14% compared with Q2 2026 | |
| ● | Expected year-over-year growth of approximately 15% to 18% compared with Q3 2025 |
PARSIPPANY, NJ, October 14, 2026 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCID: IDXG) today announced that it expects preliminary, unaudited revenue for the third quarter ended September 30, 2026 to range from $10.1 million to $10.4 million.
The expected revenue range represents an increase of approximately 11% to 14% compared with revenue of $9.1 million for the second quarter of 2026 and an increase of approximately 15% to 18% compared with revenue of $8.8 million for the third quarter of 2025.
The estimated revenue presented in this release is preliminary and unaudited, is based on information currently available to management, and remains subject to completion of the Company’s quarter-end closing procedures and review by the Company’s independent registered public accounting firm. Actual results may differ, including materially, from the range presented above. The Company expects to report complete financial results for the third quarter of 2026 at a later date.
About Interpace Biosciences
Interpace Biosciences is an emerging leader in enabling personalized medicine through specialized molecular diagnostic tests and related services. The Company’s commercialized thyroid tests include ThyGeNEXT® and ThyraMIR®v2, which are used together to support the evaluation of indeterminate thyroid nodules. For more information, please visit www.interpace.com.
Free Writing Prospectus
The issuer has filed a registration statement (including a prospectus) with the Securities and Exchange Commission (SEC) for the offering to which this free writing prospectus communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling 612-326-1305. You may also access the registration statement (including the prospectus) through the following link:
https://www.sec.gov/Archives/edgar/data/1054102/000149315226045187/forms-1a.htm
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding the Company’s expected revenue for the third quarter of 2026 and the timing of its complete financial results. These statements are based on management’s current expectations and information available as of the date of this release and are subject to risks, uncertainties, closing adjustments and other factors that could cause actual results to differ materially. Such factors include those described under “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. The preliminary, unaudited financial information in this release has not been reviewed by the Company’s independent registered public accounting firm and is subject to change as the Company completes its quarter-end closing and review procedures. The Company’s expected revenues for the third quarter of 2026 may not be indicative of the Company’s net income for such period or for full year results. Readers should not place undue reliance on these forward-looking statements. The Company undertakes no obligation to update any forward-looking statement, except as required by law.
Contacts
Investor Relations
Interpace Biosciences, Inc.
(855) 776-6419
Info@Interpace.com
| Page 1 |